Increasing prevalence of cancer in the region is the key factor that will drive Asia Pacific cell line development market growth. India has third highest number of cancer cases among women, after China. Growing adoption of vaccines and monoclonal antibodies in treatment of cancer and other chronic disease will fuel the demand for cell line cultures thereby augmenting cell line development business growth. According to the Graphical Research new growth forecast report titled “Asia Pacific Cell Line Development Market analysis based on Product, Source, Cell Line, Application, Regional Outlook – Industry Size, Share, Growth Trends & Forecast, 2018 – 2024, Estimated to Exceed USD 1.9 billion By 2024. Advancement in cell line development techniques is another positive impact rendering factor in cell line development market growth. Availability of advanced methods to enable faster and higher production of cell lines will contribute to industry growth. However, issues related to stem cell research and complex regulatory scenario might impede the cell line development market growth over the analysis period.
Request for a sample of this report @ https://www.graphicalresearch.com/request/1065/sample
Reagents and media product segment dominated the market with 53.8% revenue share in 2017 and is projected to show robust growth during the forthcoming period. Reagents and media are widely used in drug discovery, tissue engineering and other research applications. Rising demand for biological buffers, freezing reagents and dissociation reagents for research purpose will foster segmental growth over the analysis period.
Chapter 1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
22.214.171.124. Paid sources
126.96.36.199. Unpaid sources
Chapter 2. Executive Summary
2.1. Asia-Pacific cell line development market industry 3600 synopsis, 2013 – 2024
Chapter 3. Asia-Pacific Cell Line Development Market Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 – 2024
3.3. Industry impact forces
3.3.1. Growth drivers
188.8.131.52. Growing vaccine production
184.108.40.206. Increasing number of cancer incidences
220.127.116.11. Extended applications of biotechnology sector
18.104.22.168. Patent expiration of blockbuster biologics leading to innovations in the field
22.214.171.124. Escalating demand for monoclonal antibodies in Asia Pacific
126.96.36.199. Technological advancements in cell line development
3.3.2. Industry pitfalls & challenges
188.8.131.52. Growing concerns related to stem cell research
184.108.40.206. Complex regulatory landscape
3.4. Growth potential analysis
3.4.1. By product
3.4.2. By source
3.4.3. By cell-line type
3.4.4. By application
3.5. Competitive landscape, 2017
3.5.1. Strategy dashboard
3.6. Porter’s analysis
3.7. PESTEL analysis
Browse key industry insights along with Full TOC @ https://www.graphicalresearch.com/table-of-content/1065/asia-pacific-cell-line-development-market
Hybridomas was the second largest cell line type segment in 2017. The market is expected to show lucrative CAGR of 14.2% over the forecast period due to advantages associated with it such as ability to grow continuously, combination of two different types of cells, and production of pure antibodies on a large-scale.
Bioproduction application segment accounted for USD 347.0 million in 2017 and will witness significant growth during the forthcoming years. Advent of rDNA technology has drastically increased the demand for biological products for disease treatment. Wide adoption of advanced technologies in production of monoclonal antibodies, peptides, therapeutic hormones and other biological products will stimulate bioproduction segment growth.
Japan cell line development market dominated the Asia Pacific market with USD 207.3 million revenue in 2017 and will grow considerably over the analysis timeframe. The growth is attributable to increasing demand for vaccines and monoclonal antibodies for treatment of numerous chronic diseases. Technological developments in biotechnology industry will fuel the demand for cell cultures thereby driving business growth. Increasing healthcare expenditure coupled with growing demand for advanced treatments will further accelerate the regional growth.
Key industry players operating in Asia Pacific cell line development market are GE Healthcare, Thermo Fisher Scientific, Lonza Group, Sigma-Aldrich Corporation (Merck), WuXi AppTec, Sartorius, Corning, Selexis, EuBiologics, Patheon, Samsung Biologics, GVK BIO, Progenitor Cell Therapy (PCT), and Abzena. Industry players are focusing on strategic partnerships, mergers, acquisitions and new product launch to enhance existing product portfolio and capitalize on market opportunities.
Segments We Cover:
Asia Pacific Cell Line Development Market, By Product
- Reagents and media
Asia Pacific Cell Line Development Market, By Source
Asia Pacific Cell Line Development Market, By Cell Line Type
- Recombinant cell lines
- Continuous cell lines
- Primary cell lines
Asia Pacific Cell Line Development Market, By Application
- Drug discovery
- Toxicity testing
- Tissue engineering
Make an Inquiry for purchasing this Report @ https://www.graphicalresearch.com/request/1065/inquiry-before-buying
North America cell line development market was valued at USD 1.1 billion in 2017 and is expected to witness growth of more than 12.5% CAGR from 2018 to 2024 : https://www.graphicalresearch.com/industry-insights/1067/north-america-cell-line-development-market
Europe cell line development market was valued at USD 0.9 billion in 2017 and is expected to witness growth of more than 12.5% CAGR from 2018 to 2024 : https://www.graphicalresearch.com/industry-insights/1066/europe-cell-line-development-market
About Graphical Research:
Graphical Research is a business research firm that provides industry insights, market forecast and strategic inputs through granular research reports and advisory services. We publish targeted research reports with an aim to address varied customer needs, from market penetration and entry strategies to portfolio management and strategic outlook. We understand that business requirements are unique: our syndicate reports are designed to ensure relevance for industry participants across the value chain. We also provide custom reports that are tailored to the exact needs of the customer, with dedicated analyst support across the purchase lifecycle.